https://www.biocentury.com/articles?utm_source=bc_rss&utm_medium=rssBioCentury feeden-USCopyright 2026 BioCentury, Inc.RSS Generatorhttps://us-west-2-biocentury.graphassets.com/AqjgGpburRt67lm6SEY2Oz/z8oGLhcsSyi6zlYTKFwihttps://www.biocentury.com/articles?utm_source=bc_rss&utm_medium=rsshttps://www.biocentury.com/article/659197/multi-regional-trials-have-yet-to-become-the-normhttps://www.biocentury.com/article/659197/multi-regional-trials-have-yet-to-become-the-norm?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTEMULTI-REGIONAL TRIALS HAVE YET TO BECOME THE NORMBio€quity Europe preview: Scene Setter analyzes single- vs. multi-regional clinical trialsTue, 21 Apr 2026 18:23:38 -0700https://www.biocentury.com/article/659168/elevara-targeting-a-non-immune-driver-of-rheumatoid-arthritishttps://www.biocentury.com/article/659168/elevara-targeting-a-non-immune-driver-of-rheumatoid-arthritis?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EMERGING COMPANY PROFILEELEVARA: TARGETING A NON-IMMUNE DRIVER OF RHEUMATOID ARTHRITISU.K. biotech aims to deliver CDK4/6 inhibitor with wider therapeutic window than cancer therapies in the classTue, 21 Apr 2026 17:58:41 -0700https://www.biocentury.com/article/659185/recent-megadeals-reset-the-high-end-of-private-biotech-m-ahttps://www.biocentury.com/article/659185/recent-megadeals-reset-the-high-end-of-private-biotech-m-a?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTERECENT MEGADEALS RESET THE HIGH END OF PRIVATE BIOTECH M&ATwo biggest upfront payments for venture-backed biotech takeouts came this month; Kelonia’s was 65x the capital it raisedTue, 21 Apr 2026 15:23:54 -0700https://www.biocentury.com/article/659195/neurona-takeout-adds-to-ucb-s-epilepsy-portfolio-deals-reporthttps://www.biocentury.com/article/659195/neurona-takeout-adds-to-ucb-s-epilepsy-portfolio-deals-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSNEURONA TAKEOUT ADDS TO UCB’S EPILEPSY PORTFOLIO: DEALS REPORTPlus: Lilly buys dual-payload ADC developer CrossBridge; Kelonia takeout is latest in vivo CAR T acquisition; and moreTue, 21 Apr 2026 14:20:14 -0700https://www.biocentury.com/article/659181/trump-s-psychedelic-order-tests-review-normshttps://www.biocentury.com/article/659181/trump-s-psychedelic-order-tests-review-norms?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWTRUMP’S PSYCHEDELIC ORDER TESTS REVIEW NORMSAtypical policymaking process raises concerns about rigor, precedent and politicization of regulatory decisionsMon, 20 Apr 2026 18:39:32 -0700https://www.biocentury.com/article/659183/kelonia-kailera-pyschedelics-and-t-cell-engagers-a-biocentury-podcasthttps://www.biocentury.com/article/659183/kelonia-kailera-pyschedelics-and-t-cell-engagers-a-biocentury-podcast?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSKELONIA, KAILERA, PYSCHEDELICS AND T CELL ENGAGERS — A BIOCENTURY PODCASTLilly’s $3.25B deal for CAR T company, obesity play’s bumper IPO and moreMon, 20 Apr 2026 17:54:07 -0700https://www.biocentury.com/article/659180/nektar-s-phase-ii-alopecia-extension-reveals-late-responders-to-il-2-therapyhttps://www.biocentury.com/article/659180/nektar-s-phase-ii-alopecia-extension-reveals-late-responders-to-il-2-therapy?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTNEKTAR’S PHASE II ALOPECIA EXTENSION REVEALS LATE RESPONDERS TO IL-2 THERAPYBioCentury’s Clinical Report April 15–20Mon, 20 Apr 2026 17:32:47 -0700https://www.biocentury.com/article/659178/from-brushes-with-insolvency-to-record-3-25b-takeout-kelonia-broadens-lilly-s-in-vivo-car-t-pipelinehttps://www.biocentury.com/article/659178/from-brushes-with-insolvency-to-record-3-25b-takeout-kelonia-broadens-lilly-s-in-vivo-car-t-pipeline?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSFROM BRUSHES WITH INSOLVENCY TO RECORD $3.25B TAKEOUT, KELONIA BROADENS LILLY’S IN VIVO CAR T PIPELINELargest M&A deal ever for a private, venture-backed biopharma generates huge return for Venrock, fellow investorsMon, 20 Apr 2026 15:38:41 -0700https://www.biocentury.com/article/659175/moses-named-chair-of-grey-wolf-zong-joining-harbour-biomedhttps://www.biocentury.com/article/659175/moses-named-chair-of-grey-wolf-zong-joining-harbour-biomed?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSMOSES NAMED CHAIR OF GREY WOLF; ZONG JOINING HARBOUR BIOMEDRemembering a trio of European pioneersFri, 17 Apr 2026 16:37:04 -0700https://www.biocentury.com/article/659173/fda-s-budget-proposal-include-policy-wish-listhttps://www.biocentury.com/article/659173/fda-s-budget-proposal-include-policy-wish-list?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWFDA’S BUDGET PROPOSAL INCLUDE POLICY WISH LISTAgency seeking to make pediatric priority review vouchers permanent, boot industry off advisory committeesFri, 17 Apr 2026 16:34:49 -0700https://www.biocentury.com/article/659170/kailera-obesity-play-with-china-roots-upsizes-ipo-putting-it-among-biggest-ever-public-equity-reporthttps://www.biocentury.com/article/659170/kailera-obesity-play-with-china-roots-upsizes-ipo-putting-it-among-biggest-ever-public-equity-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEKAILERA, OBESITY PLAY WITH CHINA ROOTS, UPSIZES IPO, PUTTING IT AMONG BIGGEST EVER: PUBLIC EQUITY REPORTPlus: Tools company Alamar lists on NASDAQ as queue swells; Revolution’s massive follow-on; and moreFri, 17 Apr 2026 14:18:38 -0700https://www.biocentury.com/article/659161/aacr-spotlights-dual-payload-adcs-as-the-modality-nears-the-clinichttps://www.biocentury.com/article/659161/aacr-spotlights-dual-payload-adcs-as-the-modality-nears-the-clinic?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTAACR SPOTLIGHTS DUAL-PAYLOAD ADCS AS THE MODALITY NEARS THE CLINICMore than 40 abstracts showcase designs intended to counter payload resistance and tumor heterogeneityFri, 17 Apr 2026 13:19:51 -0700https://www.biocentury.com/article/659150/forbion-s-slootweg-on-europe-s-funding-environmenthttps://www.biocentury.com/article/659150/forbion-s-slootweg-on-europe-s-funding-environment?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEFORBION’S SLOOTWEG ON EUROPE’S FUNDING ENVIRONMENTSlootweg also details Forbion’s meteoric rise to become the largest independent European VC, and hunting for new assets in AsiaFri, 17 Apr 2026 09:38:42 -0700https://www.biocentury.com/article/659151/autoimmune-t-cell-engagers-diverge-from-their-oncology-rootshttps://www.biocentury.com/article/659151/autoimmune-t-cell-engagers-diverge-from-their-oncology-roots?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTAUTOIMMUNE T CELL ENGAGERS DIVERGE FROM THEIR ONCOLOGY ROOTSAs the pipeline expands, developers are splitting between modified cancer assets and autoimmune-first formatsThu, 16 Apr 2026 16:54:33 -0700https://www.biocentury.com/article/659007/scala-biodesign-embedding-biologic-design-into-pharma-r-d-workflowshttps://www.biocentury.com/article/659007/scala-biodesign-embedding-biologic-design-into-pharma-r-d-workflows?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EMERGING COMPANY PROFILESCALA BIODESIGN: EMBEDDING BIOLOGIC DESIGN INTO PHARMA R&D WORKFLOWSIsraeli biotech’s $16M series A will support global expansion of AI biologics platform ScalaOSThu, 16 Apr 2026 15:58:40 -0700https://www.biocentury.com/article/659160/now-in-clinic-neomorph-heads-into-aacr-with-100m-series-b-venture-reporthttps://www.biocentury.com/article/659160/now-in-clinic-neomorph-heads-into-aacr-with-100m-series-b-venture-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCENOW IN CLINIC, NEOMORPH HEADS INTO AACR WITH $100M SERIES B: VENTURE REPORTPlus: Rounds for Terremoto, Adcendo, Beeline and moreThu, 16 Apr 2026 15:35:51 -0700https://www.biocentury.com/article/659153/fda-s-peptide-plans-reinforce-concerns-about-ideology-politics-influencing-its-decisionshttps://www.biocentury.com/article/659153/fda-s-peptide-plans-reinforce-concerns-about-ideology-politics-influencing-its-decisions?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONFDA’S PEPTIDE PLANS REINFORCE CONCERNS ABOUT IDEOLOGY, POLITICS INFLUENCING ITS DECISIONS Agency moves toward relaxing restrictions on untested peptidesWed, 15 Apr 2026 17:53:05 -0700https://www.biocentury.com/article/659155/structure-hires-metsera-alum-lang-as-coo-general-counselhttps://www.biocentury.com/article/659155/structure-hires-metsera-alum-lang-as-coo-general-counsel?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSSTRUCTURE HIRES METSERA ALUM LANG AS COO, GENERAL COUNSELIrish BBB shuttle play Aerska adds chief platform officers, Evotec hires COO, and more Wed, 15 Apr 2026 17:35:11 -0700https://www.biocentury.com/article/659140/a-32-year-look-at-biotech-s-capital-expansionhttps://www.biocentury.com/article/659140/a-32-year-look-at-biotech-s-capital-expansion?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTEA 32-YEAR LOOK AT BIOTECH’S CAPITAL EXPANSIONHalf of all biotech equity capital raised since 1994 came in the last eight yearsWed, 15 Apr 2026 13:23:03 -0700https://www.biocentury.com/article/659119/u-s-still-top-spot-for-phase-i-trials-but-china-leads-in-i-i-metabolic-diseasehttps://www.biocentury.com/article/659119/u-s-still-top-spot-for-phase-i-trials-but-china-leads-in-i-i-metabolic-disease?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTEU.S. STILL TOP SPOT FOR PHASE I TRIALS, BUT CHINA LEADS IN I&I, METABOLIC DISEASEAn analysis of Phase I trials from 2021-25, across disease categoriesWed, 15 Apr 2026 10:05:00 -0700https://www.biocentury.com/article/659116/remembering-sofinnova-s-denis-lucquin-father-of-french-biotechhttps://www.biocentury.com/article/659116/remembering-sofinnova-s-denis-lucquin-father-of-french-biotech?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSREMEMBERING SOFINNOVA’S DENIS LUCQUIN, FATHER OF FRENCH BIOTECHInvestor helped build ecosystem in France and beyondTue, 14 Apr 2026 18:11:23 -0700https://www.biocentury.com/article/659144/novartis-narasimhan-joins-anthropic-boardhttps://www.biocentury.com/article/659144/novartis-narasimhan-joins-anthropic-board?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSNOVARTIS’ NARASIMHAN JOINS ANTHROPIC BOARDBioCentury’s latest roundup of management changes across the biotech industryTue, 14 Apr 2026 17:42:33 -0700https://www.biocentury.com/article/659142/zentalis-leads-movers-in-trio-of-ovarian-cancer-updateshttps://www.biocentury.com/article/659142/zentalis-leads-movers-in-trio-of-ovarian-cancer-updates?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTZENTALIS LEADS MOVERS IN TRIO OF OVARIAN CANCER UPDATESBioCentury’s clinical report April 7–14Tue, 14 Apr 2026 16:22:32 -0700https://www.biocentury.com/article/658973/psoriasis-paves-the-way-for-next-generation-tyk2-inhibitors-in-autoimmunityhttps://www.biocentury.com/article/658973/psoriasis-paves-the-way-for-next-generation-tyk2-inhibitors-in-autoimmunity?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTPSORIASIS PAVES THE WAY FOR NEXT-GENERATION TYK2 INHIBITORS IN AUTOIMMUNITYWith positive Phase III data, both Takeda and Alumis are placing broader bets on the TYK2 mechanismTue, 14 Apr 2026 14:03:26 -0700https://www.biocentury.com/article/659127/fda-s-fih-plans-plus-billion-dollar-deals-funds-a-biocentury-podcasthttps://www.biocentury.com/article/659127/fda-s-fih-plans-plus-billion-dollar-deals-funds-a-biocentury-podcast?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONFDA’S FIH PLANS. PLUS: BILLION-DOLLAR DEALS, FUNDS — A BIOCENTURY PODCASTGilead, Neurocrine bolt on biotechs; new funds from Blackstone, JeitoMon, 13 Apr 2026 17:04:37 -0700https://www.biocentury.com/article/659121/revmed-s-pancreatic-cancer-win-strengthens-the-case-for-targeting-ras-onhttps://www.biocentury.com/article/659121/revmed-s-pancreatic-cancer-win-strengthens-the-case-for-targeting-ras-on?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTREVMED’S PANCREATIC CANCER WIN STRENGTHENS THE CASE FOR TARGETING RAS(ON)Daraxonrasib’s survival benefit positions the active-state inhibitor for a potential first-in-class PDAC approvalMon, 13 Apr 2026 17:03:02 -0700https://www.biocentury.com/article/659131/biotech-executive-combative-conservative-hemmati-may-head-cberhttps://www.biocentury.com/article/659131/biotech-executive-combative-conservative-hemmati-may-head-cber?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONBIOTECH EXECUTIVE, COMBATIVE CONSERVATIVE HEMMATI MAY HEAD CBERHouman Hemmati is a leading contender to replace Vinay Prasad as CBER directorMon, 13 Apr 2026 15:48:14 -0700https://www.biocentury.com/article/659123/ipo-queue-grows-as-seaport-hemab-line-up-nasdaq-offeringshttps://www.biocentury.com/article/659123/ipo-queue-grows-as-seaport-hemab-line-up-nasdaq-offerings?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEIPO QUEUE GROWS AS SEAPORT, HEMAB LINE UP NASDAQ OFFERINGSVolatility risk may be abating; Kailera, Alamar propose termsMon, 13 Apr 2026 15:29:17 -0700https://www.biocentury.com/article/659129/regeneron-enters-radiotherapy-gilead-buys-another-biotech-and-more-deals-reporthttps://www.biocentury.com/article/659129/regeneron-enters-radiotherapy-gilead-buys-another-biotech-and-more-deals-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSREGENERON ENTERS RADIOTHERAPY, GILEAD BUYS ANOTHER BIOTECH, AND MORE: DEALS REPORTSelect biopharma deals, April 7-13Mon, 13 Apr 2026 15:12:12 -0700https://www.biocentury.com/article/659111/fibrosis-company-avalyn-seeks-nasdaq-listing-amid-volatility-finance-reporthttps://www.biocentury.com/article/659111/fibrosis-company-avalyn-seeks-nasdaq-listing-amid-volatility-finance-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEFIBROSIS COMPANY AVALYN SEEKS NASDAQ LISTING AMID VOLATILITY: FINANCE REPORTPlus: Venture rounds for Stipple, Sidewinder and Life; a follow-on for Forte; and moreFri, 10 Apr 2026 14:48:07 -0700https://www.biocentury.com/article/659104/stipple-epitope-level-precision-for-safer-cancer-therapieshttps://www.biocentury.com/article/659104/stipple-epitope-level-precision-for-safer-cancer-therapies?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EMERGING COMPANY PROFILESTIPPLE: EPITOPE-LEVEL PRECISION FOR SAFER CANCER THERAPIESStipple is mapping the cancer surfaceome at epitope-level resolution to generate tumor-specific binders that spare healthy tissueFri, 10 Apr 2026 13:35:15 -0700https://www.biocentury.com/article/659102/blackstone-s-galakatos-on-scaling-deals-with-6-3b-fund-broader-furtherhttps://www.biocentury.com/article/659102/blackstone-s-galakatos-on-scaling-deals-with-6-3b-fund-broader-further?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEBLACKSTONE’S GALAKATOS ON SCALING DEALS WITH $6.3B FUND: ‘BROADER, FURTHER’With a new fund 40% larger than its last, the life sciences investor will press ahead with two discrete investment modelsFri, 10 Apr 2026 08:27:12 -0700https://www.biocentury.com/article/659099/industry-shifts-fda-from-punitive-to-reward-based-america-first-pdufa-policyhttps://www.biocentury.com/article/659099/industry-shifts-fda-from-punitive-to-reward-based-america-first-pdufa-policy?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWINDUSTRY SHIFTS FDA FROM PUNITIVE TO REWARD-BASED AMERICA FIRST PDUFA POLICYInstead of a $10M penalty for conducting first-in-human trials overseas, reauthorized PDUFA would cut fees by $2M for domestic FIH trialsThu, 09 Apr 2026 15:19:13 -0700https://www.biocentury.com/article/659098/science-spotlight-altos-labs-cognition-enhancerhttps://www.biocentury.com/article/659098/science-spotlight-altos-labs-cognition-enhancer?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONSCIENCE SPOTLIGHT: ALTOS LABS’ COGNITION ENHANCERPlus: A map of pain circuitry, a safer mu-opioid receptor agonist, and a small molecule that could prevent weigh rebound after GLP-1s Thu, 09 Apr 2026 13:32:35 -0700https://www.biocentury.com/article/659083/front-row-with-biocentury-asia-innovation-and-dealmaking-beyond-chinahttps://www.biocentury.com/article/659083/front-row-with-biocentury-asia-innovation-and-dealmaking-beyond-china?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSFRONT ROW WITH BIOCENTURY: ASIA INNOVATION AND DEALMAKING BEYOND CHINAHow South Korea and Japan are building biotech ecosystems with growing global reachThu, 09 Apr 2026 09:30:33 -0700https://www.biocentury.com/article/659001/biogen-strengthens-case-for-bdca2-as-a-cutaneous-lupus-targethttps://www.biocentury.com/article/659001/biogen-strengthens-case-for-bdca2-as-a-cutaneous-lupus-target?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTBIOGEN STRENGTHENS CASE FOR BDCA2 AS A CUTANEOUS LUPUS TARGETSecond Phase II success supports targeted approach in refractory patientsWed, 08 Apr 2026 17:27:00 -0700https://www.biocentury.com/article/659073/tackling-translation-the-parker-institute-modelhttps://www.biocentury.com/article/659073/tackling-translation-the-parker-institute-model?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONTACKLING TRANSLATION: THE PARKER INSTITUTE MODELAs it approaches its tenth birthday, the Parker Institute is showing the power of focusing on translationWed, 08 Apr 2026 15:13:26 -0700https://www.biocentury.com/article/659049/with-1b-fund-jeito-looks-for-plug-and-play-biotechs-ripe-for-pharma-takeoutshttps://www.biocentury.com/article/659049/with-1b-fund-jeito-looks-for-plug-and-play-biotechs-ripe-for-pharma-takeouts?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEWITH €1B FUND, JEITO LOOKS FOR ‘PLUG-AND-PLAY’ BIOTECHS RIPE FOR PHARMA TAKEOUTSFrench VC firm looks to deliver growth capital to European biotechsWed, 08 Apr 2026 00:50:14 -0700https://www.biocentury.com/article/659076/two-1b-deals-in-2q26-s-first-weekhttps://www.biocentury.com/article/659076/two-1b-deals-in-2q26-s-first-week?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTETWO $1B+ DEALS IN 2Q26’S FIRST WEEKApril’s first week has already matched or exceeded the full-quarter total seen in three quarters since 2019Tue, 07 Apr 2026 15:59:12 -0700https://www.biocentury.com/article/659064/gilead-s-3b-tubulis-takeout-to-add-adc-depth-beyond-trodelvyhttps://www.biocentury.com/article/659064/gilead-s-3b-tubulis-takeout-to-add-adc-depth-beyond-trodelvy?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSGILEAD’S $3B TUBULIS TAKEOUT TO ADD ADC DEPTH BEYOND TRODELVYDeal brings two clinical programs and a conjugation platform to an oncology portfolio with little behind its anchor ADCTue, 07 Apr 2026 15:46:25 -0700https://www.biocentury.com/article/658908/precision-mtor-targeting-aims-to-widen-the-window-in-tsc-epilepsyhttps://www.biocentury.com/article/658908/precision-mtor-targeting-aims-to-widen-the-window-in-tsc-epilepsy?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTPRECISION MTOR TARGETING AIMS TO WIDEN THE WINDOW IN TSC EPILEPSYSelective mTORC1 inhibition emerges as a strategy to improve safety and efficacy in rare epilepsy disorderTue, 07 Apr 2026 09:46:46 -0700https://www.biocentury.com/article/659055/fda-proposing-pathway-to-cut-time-to-first-in-human-trialshttps://www.biocentury.com/article/659055/fda-proposing-pathway-to-cut-time-to-first-in-human-trials?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONFDA PROPOSING PATHWAY TO CUT TIME TO FIRST-IN-HUMAN TRIALSFDA’s proposal is more ambitious than policies implemented in Australia, China, U.K., but could take years to implementMon, 06 Apr 2026 16:31:36 -0700https://www.biocentury.com/article/659040/2q-markets-preview-tariffs-and-biotech-takeouts-a-biocentury-podcasthttps://www.biocentury.com/article/659040/2q-markets-preview-tariffs-and-biotech-takeouts-a-biocentury-podcast?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCE2Q MARKETS PREVIEW, TARIFFS AND BIOTECH TAKEOUTS — A BIOCENTURY PODCASTOutlook for biotech as it looks to continue the growth of 2H25Mon, 06 Apr 2026 16:10:28 -0700https://www.biocentury.com/article/659048/alzheimer-s-company-korsana-heads-to-nasdaq-via-merger-deals-reporthttps://www.biocentury.com/article/659048/alzheimer-s-company-korsana-heads-to-nasdaq-via-merger-deals-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSALZHEIMER’S COMPANY KORSANA HEADS TO NASDAQ VIA MERGER: DEALS REPORTPlus: Gilead, Galapagos reach agreement to advance Ouro bispecific; three deals add up to almost $15B; and moreMon, 06 Apr 2026 14:12:44 -0700https://www.biocentury.com/article/659037/lipocine-adds-to-ppd-setbacks-as-tepezza-scores-batoclimab-misses-in-tedhttps://www.biocentury.com/article/659037/lipocine-adds-to-ppd-setbacks-as-tepezza-scores-batoclimab-misses-in-ted?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTLIPOCINE ADDS TO PPD SETBACKS AS TEPEZZA SCORES, BATOCLIMAB MISSES IN TEDBioCentury’s clinical report for March 31 – April 6Mon, 06 Apr 2026 14:02:31 -0700https://www.biocentury.com/article/659043/soleno-buyout-for-2-9b-puts-neurocrine-s-strength-behind-prader-willi-drughttps://www.biocentury.com/article/659043/soleno-buyout-for-2-9b-puts-neurocrine-s-strength-behind-prader-willi-drug?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSSOLENO BUYOUT FOR $2.9B PUTS NEUROCRINE’S STRENGTH BEHIND PRADER-WILLI DRUGWith little near-term competition, hyperphagia treatment figures to continue sales growthMon, 06 Apr 2026 13:50:30 -0700https://www.biocentury.com/article/659033/ambrosia-syneron-move-toward-clinic-with-nine-digit-series-b-rounds-finance-reporthttps://www.biocentury.com/article/659033/ambrosia-syneron-move-toward-clinic-with-nine-digit-series-b-rounds-finance-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEAMBROSIA, SYNERON MOVE TOWARD CLINIC WITH NINE-DIGIT SERIES B ROUNDS: FINANCE REPORTPlus: Kailera’s IPO filing, Blackstone’s new fund, Celldex’s follow-on, and moreFri, 03 Apr 2026 16:44:11 -0700https://www.biocentury.com/article/659029/rocket-gene-therapy-among-fda-s-march-approvals-earns-prvhttps://www.biocentury.com/article/659029/rocket-gene-therapy-among-fda-s-march-approvals-earns-prv?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTEROCKET GENE THERAPY, AMONG FDA’S MARCH APPROVALS, EARNS PRVLast month’s approvals also include four NMEsFri, 03 Apr 2026 15:58:38 -0700https://www.biocentury.com/article/659038/liver-specialist-amit-singal-joining-curve-bioscienceshttps://www.biocentury.com/article/659038/liver-specialist-amit-singal-joining-curve-biosciences?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSLIVER SPECIALIST AMIT SINGAL JOINING CURVE BIOSCIENCES  BioCentury’s latest biopharma management movesFri, 03 Apr 2026 15:40:10 -0700https://www.biocentury.com/article/659034/pharma-tariffs-pressuring-smaller-companies-to-do-mfn-dealshttps://www.biocentury.com/article/659034/pharma-tariffs-pressuring-smaller-companies-to-do-mfn-deals?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWPHARMA TARIFFS PRESSURING SMALLER COMPANIES TO DO MFN DEALSExemptions, discretion creates complexities; acquisition of assets from, outsourcing R&D to China unaffectedFri, 03 Apr 2026 15:37:51 -0700